|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_001001936, 50897850|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||91300 Da|
|Application Notes||AFAP1L2 antibody can be used for detection of AFAP1L2 by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Reconstitution & Storage||AFAP1L2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||AFAP1L2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May play a role in a signaling cascade by enhancing the kinase activity of SRC. Contributes to SRC-regulated transcription activation.|
|Tissue Location||Detected in spleen and thyroid, and at lower levels in kidney, brain, lung and pancreas|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
AFAP1L2 Antibody: AFAP1L2, also known as XB130, is structurally similar to actin-filament-associated protein (AFAP), containing several SH2- and SH3-binding motifs, two pleckstrin homology domains, a coiled-coil region, and many potential phosphorylation sites. It interacts with and is phosphorylated by c-Src tyrosine kinase. Suppression of AFAP1L2 via siRNA reduced Src activity, IL-8 production, EGF-induced phosphorylation of Akt and GSK3beta, and altered cell cycles in human lung epithelial cells suggesting that AFAP1L2 plays a role as an adaptor in the regulation of Src signal transduction and multiple cellular functions. Recent experiments have shown that AFAP1L2 is highly expressed in thyroid and is the substrate RET/PTC kinase, a thyroid-specific kinase that plays a pathogenic role in papillary thyroid cancer. Down-regulation of AFAP1L2 in these cancer cells reduced Akt activity, inhibiting cell-cycle progression and cancer cell survival in suspension, indicating that AFAP1L2 may be a valuable target in thyroid cancer therapy. At least four isoforms of AFAP1L2 are known to exist.
Xu J, Bai X-H, Lodyga M, et al. XB130, a novel adaptor protein for signal transduction. J. Biol. Chem.2007; 282:16401-12.
Lodyga M, De Falco V, Bai XH, et al. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene2009; 28:937-49.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.